birinapant

阳光醉人

来个根治药物吧

newchinabok

时间越来越近了

x321

回复 newchinabok 的帖子

这次公布这个药效吗

newchinabok

肿瘤上好像做的不成功

战天斗hbv

newchinabok 发表于 2015-4-15 19:35
肿瘤上好像做的不成功

如果肿瘤上不成功、那我觉得hbv也悬、毕竟一样的原理、肿瘤下药还猛些、
ncb你的哪的消息啊、我在推上看得好像肿瘤效果还行啊

Olivia123

Yes, they might just cover the preclinical research, in their hydrodynamic mouse model. But the announcement was written in a way that it claims that it works in the human system. Since by now they will have at least a few patients beyond the four weekly doses and the effect on hbsag should be quite  immediate, they certainly must have human data by now. He might just present these in a last slide - or not.
Would it be able that you ask them more specifically if some preliminary data on the ongoing trial will be part of the discussion?

At any rate, thank you for the effort you already made.

The fundamental difference between all the inhibitory drugs to block the HBV system, which do not destroy the source but just limit the virion or accessory protein output while they are dosed and this approach is that it aims to eliminate the source of the infection itself cccDNA or integrated.

The mechanism operative is hoped to be that a not so effective immune signal tries to initiate apoptoses in infected cells. This is a scenario that we expect in chronic HBV, particularly in e negative, because the key cd8 epitopes are adapted and mutated, so the attack CTLs are too weak to push the cell into apoptosis with the signals provided.

However a key mechanism by which the cell avoids apoptosis under stress is the production of anti apoptotic proteins, that block milder apoptotic signaling. By introducing the SMAC/DIABLO mimetic birinapant, these antiapoptotic protectors are themselves inactivated, so now apoptosis happens.

The drug has been used in several human cancer trials, side effects seem to be very mild, the worst being Bells Palsy, reversible.

The mouse data are stunning, hbsag was lost in 4 weeks. But of course the model has its limits and the human situation can be quite different.

the biggest fear was or is that the effect is too strong and if a large percentage of liver cells are infected, acute fulminant hepatitis could result.
The plan apparently is to start with patients on antivirals which are UND and also to use a very small starting dose.

Olivia123

回复 Olivia123 的帖子

他是不是说这个药已经在临床上开始使用了，针对癌症的。

战天斗hbv

Olivia123 发表于 2015-4-15 19:44
Yes, they might just cover the preclinical research, in their hydrodynamic mouse model. But the anno ...

这段话我从未在网络上搜索到过、这是你自己写的、还是转载的、内容很有趣、信息很劲爆、感谢分享！
thx！

战天斗hbv

Yes, they might just cover the preclinical research, in their hydrodynamic mouse model. But the announcement was written in a way that it claims that it works in the human system. Since by now they will have at least a few patients beyond the four weekly doses and the effect on hbsag should be quite  immediate, they certainly must have human data by now.（以下是我的猜想、不是上文标红的翻译！这段话不知道谁写的、我一直感觉、从癌症跨界到HBV、肯定是有了什么特殊的发现、比如说、治疗肝癌病人的时候、HBV清除了、偶发性的、科研人员才觉得很大可能性、对HBV有效） He might just present these in a last slide - or not.
Would it be able that you ask them more specifically if some preliminary data on the ongoing trial will be part of the discussion?

At any rate, thank you for the effort you already made.

The fundamental difference between all the inhibitory drugs to block the HBV system, which do not destroy the source but just limit the virion or accessory protein output while they are dosed and this approach is that it aims to eliminate the source of the infection itself cccDNA or integrated.

The mechanism operative is hoped to be that a not so effective immune signal tries to initiate apoptoses in infected cells. This is a scenario that we expect in chronic HBV, particularly in e negative, because the key cd8 epitopes are adapted and mutated, so the attack CTLs are too weak to push the cell into apoptosis with the signals provided.

However a key mechanism by which the cell avoids apoptosis under stress is the production of anti apoptotic proteins, that block milder apoptotic signaling. By introducing the SMAC/DIABLO mimetic birinapant, these antiapoptotic protectors are themselves inactivated, so now apoptosis happens.

The drug has been used in several human cancer trials, side effects seem to be very mild, the worst being Bells Palsy, reversible.

The mouse data are stunning, hbsag was lost in 4 weeks. But of course the model has its limits and the human situation can be quite different.

the biggest fear was or is that the effect is too strong and if a large percentage of liver cells are infected, acute fulminant hepatitis could result.（）
The plan apparently is to start with patients on antivirals which are UND and also to use a very small starting dose.

战天斗hbv

不怕药效过猛、就怕没效果、